The impact of Jinlida on blood glucose control and insulin resistance in patients with prediabetes and type 2 diabetes: a systematic review and meta-analysis of randomized controlled trials
Der Einfluss von Jinlida auf die Blutzuckerkontrolle und Insulinresistenz bei Patient:innen mit Prädiabetes und Typ-2-Diabetes: systematische Übersicht und Metaanalyse randomisierter kontrollierter Studien
Frontiers in Endocrinology · 17.11.2025 · 16
DOI: 10.3389/fendo.2025.1689640 ↗Auf einen Blick
In 20 RCTs mit 2.993 Teilnehmenden war Jinlida mit niedrigeren Glukosewerten, HbA1c und HOMA-IR verbunden als Kontrollen. Auch die Lipidwerte verbesserten sich.
Fragestellung
Wie wirksam und sicher ist Jinlida bei Prädiabetes und Typ-2-Diabetes für Blutzuckerkontrolle und Insulinresistenz?
Methode
Systematische Übersicht und Metaanalyse von RCTs; Suche in PubMed, Web of Science, Cochrane Library, Embase, Scopus, CBM, CNKI, Wanfang und VIP bis Juli 2025; RoB 2.0 und GRADE.
Ergebnisse
20 RCTs mit 2.993 Teilnehmenden. Gegenüber Kontrollen senkte JLD FBG (MD -0,97; 95 %-KI -1,40 bis -0,53), 2h-PG (-1,52; -1,89 bis -1,16), HbA1c (-0,76; -1,00 bis -0,52) und HOMA-IR (-0,78; -1,12 bis -0,44).
Einschränkungen
Unterschiedliche Evidenzsicherheit je Outcome; weitere große, hochwertige RCTs erforderlich.
Schlussfolgerung der Autor:innen
JLD kann die glykämische Kontrolle, Insulinresistenz und Lipidprofile bei Typ-2-Diabetes und Prädiabetes verbessern; die Befunde sollten wegen der variierenden Evidenzsicherheit vorsichtig interpretiert werden.
Kernaussagen
- FBG, 2h-PG, HbA1c und HOMA-IR waren unter JLD niedriger als unter Kontrollen.
- HDL-C stieg, LDL-C, TC und TG sanken unter JLD.
- Die Lipidvorteile waren bei Typ-2-Diabetes stärker.
Deutsche Zusammenfassung: KI-gestützt aus dem Original-Abstract erstellt; alle Zahlen wurden automatisch mit dem Original abgeglichen. Maßgeblich ist der Original-Abstract.
Kurz gefasst
Systematische Übersicht in der Zeitschrift Frontiers in Endocrinology, online erschienen am 17.11.2025. Verfasst von Limeng Li und 7 weiteren Autor:innen. Beteiligte Einrichtung: Tuina Department, First Teaching Hospital of Tianjin University of Traditional Chinese Medicine, Tianjin, China. Hauptthemen laut MEDLINE: Diabetes Mellitus, Type 2, Insulin Resistance, Prediabetic State, Blood Glucose. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 54 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Themen: Diabetes mellitus
Abstract (Originalsprache)
Objective
To evaluate the efficacy and safety of Jinlida (JLD) in improving glycemic control and insulin resistance in patients with prediabetes (PD) and type 2 diabetes mellitus (T2DM) through a meta-analysis of randomized controlled trials (RCTs).
Methods
Databases including PubMed, Web of Science, Cochrane Library, Embase, Scopus, CBM, CNKI, Wanfang, and VIP were searched up to July 2025. Randomized controlled trials comparing JLD with controls were included. Pooled analyses were conducted using a random-effects model. Pre-specified subgroup analyses included health status and treatment duration. Additional analyses by baseline FBG level and age were performed to explore residual heterogeneity. Multivariable meta-regression with Knapp-Hartung adjustment further examined potential moderators (e.g., background therapy, baseline FBG level). Publication bias was assessed by funnel plots, Egger’s test, and the trim-and-fill method. Risk of bias and evidence certainty were evaluated using RoB 2.0 and GRADE.
Results
A total of 20 RCTs involving 2,993 participants were included. Compared with controls, JLD significantly reduced: FBG (MD = -0.97, 95% CI: -1.40 to -0.53; p < 0.001), 2h-PG (MD = -1.52, 95% CI: -1.89 to -1.16; p < 0.001), HbA1c (MD = -0.76, 95% CI: -1.00 to -0.52; p < 0.001), HOMA-IR (MD = -0.78, 95% CI: -1.12 to -0.44, p < 0.001). In lipid outcomes, JLD improved: HDL-C (MD = 0.22, 95% CI: 0.12 to 0.32, p < 0.001), LDL-C (MD = -0.69, 95% CI: -1.05 to -0.33; p < 0.001), TC (MD = -0.57, 95% CI: -0.87 to -0.27; p < 0.001), TG (MD = -0.52, 95% CI: -0.72 to -0.31, p < 0.001). Subgroup analyses revealed that JLD produced greater glycemic improvements in shorter-duration trials and in patients with higher baseline fasting glucose (≥10 mmol/L). T2DM patients showed more pronounced reductions in HbA1c, HOMA-IR, and lipid parameters compared with PD. Additionally, JLD significantly improved HDL-C, LDL-C, TC, and TG, with lipid benefits being stronger in T2DM.
Conclusion
JLD may help improve glycemic control, insulin resistance, and lipid profiles in patients with T2DM and prediabetes. Given the varying levels of certainty in the evidence across outcomes, these findings should be interpreted cautiously. Further large-scale, high-quality RCTs are needed to confirm these findings. Systematic review registration https://www.crd.york.ac.uk/prospero/ , identifier CRD420251124510.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Tuina Department, First Teaching Hospital of Tianjin University of Traditional Chinese Medicine, Tianjin, China.
- National Administration of Traditional Chinese Medicine Level Three Laboratory for Tuina Technique Biological Effects, Tianjin, China.
- Department of Human Development, Teachers College, Columbia University, New York, NY, United States.
Zitieren
APA
Li, L., Tan, Q., Zhang, S., Huang, Y., Xu, C., Fan, S., Li, H., & Tan, T. (2025). The impact of Jinlida on blood glucose control and insulin resistance in patients with prediabetes and type 2 diabetes: a systematic review and meta-analysis of randomized controlled trials. Frontiers in Endocrinology, 16. https://doi.org/10.3389/fendo.2025.1689640
Vancouver
Li L, Tan Q, Zhang S, Huang Y, Xu C, Fan S, et al. The impact of Jinlida on blood glucose control and insulin resistance in patients with prediabetes and type 2 diabetes: a systematic review and meta-analysis of randomized controlled trials. Frontiers in Endocrinology. 2025;16. doi:10.3389/fendo.2025.1689640
BibTeX
@article{Li2025,
author = {Li, Limeng and Tan, Qingyin and Zhang, Shidong and Huang, Yingxue and Xu, Chuhan and Fan, Shun and Li, Huanan and Tan, Tao},
title = {The impact of Jinlida on blood glucose control and insulin resistance in patients with prediabetes and type 2 diabetes: a systematic review and meta-analysis of randomized controlled trials},
journal = {Frontiers in Endocrinology},
year = {2025},
volume = {16},
doi = {10.3389/fendo.2025.1689640}
}
EUVIMED